

**Materials for this course will release 02/01/2023**

---

### Intensive Studies for Recertification: Pediatric Pharmacy (Cert # L239020)

**Teaser:** The Pediatric Pharmacy Intensive Studies for Recertification Package consists of 3 activities and provides up to 4.0 contact hours of recertification credit through a high-level, interactive discussion on contemporary and emerging issues in pediatric pharmacy.

**Tag:** Certifications; Pediatric Pharmacy

---



#### ACPE Numbers:

0204-0000-22-236-H01-P

0204-0000-22-241-H01-P

0204-0000-22-269-H04-P

**Pre-Sale Date:** 01/04/2023

**Content Release Date:** 02/01/2023

**Expiration Date:** 01/30/2024

**Activity Type:** Application-based

**CE Credits:** 4.0 contact hours

**Activity Fee:** \$100 (ASHP member); \$150 (non-member)

#### Accreditation for Pharmacists



The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

*These activities were presented as part of the 2022 Midyear Clinical Meeting. Learners who claimed ACPE credit for these activities as part of that meeting, should not claim ACPE credit again.*

#### Target Audience

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

- Disparities in Sickle Cell disease
- Status epilepticus
- Bias in primary literature

#### Activity Overview

The Intensive Study Package is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in pediatric pharmacy.

The Pediatric Pharmacy Intensive Study Recertification Package consists of 3 activities (see table below) and provides up to 4.0 contact hours of continuing pharmacy education and/or recertification credit.

These activities are part of the ASHP professional development program for BCPPS recertification approved by the BPS. For pharmacists who maintain more than one certification, one of the activities is approved for multiple specialties (see table below).

#### Recertification Credit\*

Board certified pharmacists are eligible to receive up to 4.0 contact hours of recertification credit for completing this package. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

---

**Materials for this course will release 02/01/2023**

Learning Activity	ACPE Number	Contact Hours	Specialty	Recertification Assessment
Forecasting the Future: Optimizing Care and Minimizing Disparities for Patients with Sickle Cell Disease	0204-0000-22-236-H01-P	1.0 ACPE	BCPPS	TBD
Status Epilepticus in Adults and Children	0204-0000-22-241-H01-P	1.5 ACPE	BCPPS, BCCCP, BCPS	TBD
Judging an Article by Its Cover: Assessing Bias in Primary Literature	0204-0000-22-269-H04-P	1.5 ACPE	BCPPS, BCCCP, BCPS	TBD
<b>Total Contact Hours</b>		4.0 BPS		

**Forecasting the Future: Optimizing Care and Minimizing Disparities for Patients with Sickle Cell Disease**  
**0204-0000-22-236-H01-P**

**Learning Objectives**

- Summarize evidence-based recommendations in the treatment of sickle cell disease (SCD).
- Recommend novel disease-modifying therapies for patients with SCD.
- Select curative therapeutic modalities for patients with SCD.
- Identify healthcare disparities that exist for patients with SCD.

*This activity is approved for Board Certified Pediatric Pharmacist (BCPPS) recertification credit.*

**Status Epilepticus in Adults and Children**

**0204-0000-22-241-H01-P**

**Learning Objectives**

- Contrast pharmacokinetic considerations in children compared to adults with status epilepticus.
- Recommend initial benzodiazepine therapy for treatment of status epilepticus given a pediatric or adult patient case.
- Contrast second phase medications for treatment of status epilepticus.
- Given a patient case, evaluate third phase treatment options for status epilepticus.
- Design a monitoring plan for a patient receiving treatment for status epilepticus.

*This activity is approved for Board Certified Critical Care Pharmacist (BCCCP), Board Certified Pediatric Pharmacy Specialist (BCPPS), and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.*

**Judging an Article by Its Cover: Assessing Bias in Primary Literature**

**0204-0000-22-269-H04-P**

**Learning Objectives**

- Select appropriate research study design and types of errors associated with study methods.
- Explain types of bias and how to prevent occurrence when developing methods of a clinical trial.
- Based on study methodology and results of a clinical trial, determine how bias may affect analysis and interpretation of study results.
- Compare and contrast current practice regarding bias and confounders when evaluating primary literature.

*This activity is approved for Board Certified Critical Care Pharmacist (BCCCP), Board Certified Pediatric Pharmacy Specialist (BCPPS), and Board Certified Pharmacotherapy Specialist (BCPS) recertification credit.*

**Materials for this course will release 02/01/2023**

---

### Faculty

**Joshua J. Elder, PharmD, BCOP, BCPS**

Clinical Specialist - Pediatric Heme/Onc/SCT  
Director - PGY2 Oncology Pharmacy Residency  
Norton Children's Hospital  
Louisville, Kentucky

**Salia Farrokh, PharmD**

Neurocritical Care Clinical Pharmacist Specialist  
Johns Hopkins Hospital  
Ellicott City, Maryland

**Emily K. Frederick, PharmD, BCPS**

Associate Professor  
Sullivan University College of Pharmacy and Health Sciences  
Louisville, Kentucky

**Kaitlin M. Hughes, PharmD, BCPPS**

Clinical Pharmacist Pediatric Critical Care  
Riley Hospital for Children at IU Health  
Indianapolis, Indiana

### Reviewers

Mary Hess, PharmD, BCCCP, FASHP, FCCM, FCCP\*  
Peter N. Johnson, PharmD, BCPPS, BCPS, FCCM, FPPAG\*  
Jamie L. Miller, PharmD, BCPPS\*  
Douglas Slain, PharmD, BCPS, FASHP\*  
Paul M. Szumita, PharmD, BCCCP, BCPS, FASHP, FCCM\*  
Jennifer L. Thackray, PharmD, BCPPS, BCPS\*

### \*Content Matter Experts

#### Field Testers

Hakeem Abayomi, BS, PharmD, BCPS, BCPPS, BCIDP, BCCCP  
Erin Anderson, PharmD  
Elizabeth Autry, PharmD, BCPPS  
Meghan Baldo, PharmD, BCPPS  
Leanna Barker, PharmD, BCPPS  
Jessica Bergsbaken, PharmD, BCPPS  
Deanna Boone James, PharmD, CPh, BCPS, BCCCP  
Alexander Brorby, PharmD, BCPS  
Samantha Chang, PharmD  
Da Won Choi, PharmD, BCPPS  
Jesse Cramer, PharmD, BCPPS  
Allie Dothager, PharmD, BCPS  
Norm Fenn, PharmD, BCPS, BCPPS  
Kristen Finical, PharmD, BCPPS  
Adam Gaines, PharmD BCPS  
Aaron Harthan, PharmD, BCPPS  
Mylinh Ho, PharmD, BCPS, BCCCP  
Pui Man (Julia) Ho, PharmD, BCPPS

Katie Hughes, PharmD, BCPPS  
Malia Kleespies, PharmD, BCPPS  
Ekaterina Kurdyukova, PharmD, BCPPS  
Courtney Lang, PharmD, BCPS, BCCCP  
Dylan Mochizuki, PharmD, BCPPS  
Cody Moseman, PharmD  
Zarema Muratova, BCPPS  
Ashley Nebbia, PharmD, BCPPS  
Nicole Palazzolo, PharmD, BCPPS  
Amanda Penland, PharmD, BCPPS  
Alyssa Polotti, PharmD, BCCCP  
Isabel Porto, PharmD, BCPPS  
Christy Rooks, BCPS, BCCCP  
Marie Rossique-Gonzalez, PharmD, BCPPS  
Anna Simmont, PharmD, BCPS, BCPPS  
Autumn Aspen Wall, PharmD, BCPPS  
Abigail Yancey, PharmD, FCCP, BCPS

### Disclosures

In accordance with our accreditor's Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.

**Materials for this course will release 02/01/2023**

---

**Methods and CE Requirements**

Activities consist of audio/video/PDF files, an attestation statement, and activity evaluation. Learners must review all content and complete the attestation statement and course evaluation to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

**System Technical Requirements**

Learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the [minimum technical and system requirements](#) for learning activities.

**Development**

These activities were developed by ASHP.